New York State Common Retirement Fund Increases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Common Retirement Fund grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 41.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,516 shares of the company’s stock after purchasing an additional 25,849 shares during the period. New York State Common Retirement Fund owned about 0.27% of TransMedics Group worth $6,908,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Cutler Group LLC CA boosted its holdings in TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares during the period. RiverPark Advisors LLC acquired a new position in shares of TransMedics Group during the third quarter worth about $60,000. Van ECK Associates Corp raised its holdings in TransMedics Group by 39.0% in the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock valued at $116,000 after acquiring an additional 597 shares in the last quarter. Headlands Technologies LLC purchased a new position in TransMedics Group in the third quarter worth approximately $180,000. Finally, Yarbrough Capital LLC acquired a new position in TransMedics Group during the 4th quarter worth approximately $201,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 2.9 %

Shares of TransMedics Group stock opened at $127.99 on Friday. The firm’s fifty day simple moving average is $85.54 and its 200-day simple moving average is $76.85. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $129.66.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The company had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. During the same period in the previous year, the business posted ($0.08) earnings per share. TransMedics Group’s quarterly revenue was up 132.9% on a year-over-year basis. As a group, analysts anticipate that TransMedics Group, Inc. will post 0.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Oppenheimer raised their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday. Canaccord Genuity Group increased their price objective on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday. TD Cowen boosted their target price on TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Morgan Stanley raised their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $119.00.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 63,260 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total value of $6,866,240.40. Following the transaction, the insider now owns 9,792 shares of the company’s stock, valued at $1,062,823.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Tamer I. Khayal sold 63,260 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the sale, the insider now owns 9,792 shares in the company, valued at approximately $1,062,823.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 736 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the transaction, the insider now owns 14,375 shares in the company, valued at $1,295,043.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 236,378 shares of company stock valued at $23,633,449. 7.00% of the stock is owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.